Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 2Xls
2D Structure
Also known as: Trolamine, 102-71-6, 2,2',2''-nitrilotriethanol, Sterolamide, Tris(2-hydroxyethyl)amine, Daltogen
Molecular Formula
C6H15NO3
Molecular Weight
149.19  g/mol
InChI Key
GSEJCLTVZPLZKY-UHFFFAOYSA-N
FDA UNII
9O3K93S3TK

Triethanolamine is a metabolite found in the aging mouse brain.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[bis(2-hydroxyethyl)amino]ethanol
2.1.2 InChI
InChI=1S/C6H15NO3/c8-4-1-7(2-5-9)3-6-10/h8-10H,1-6H2
2.1.3 InChI Key
GSEJCLTVZPLZKY-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C(CO)N(CCO)CCO
2.2 Other Identifiers
2.2.1 UNII
9O3K93S3TK
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2,2',2''-nitrilotriethanol

2. Triethanolamine Acetate

3. Triethanolamine Citrate

4. Triethanolamine Citrate (1:1)

5. Triethanolamine Copper Salt

6. Triethanolamine Hydrochloride

7. Triethanolamine Iodohydrate

8. Triethanolamine Maleate

9. Triethanolamine Phosphate

10. Triethanolamine Sulfate

11. Triethanolamine Sulfate (2:1)

12. Triethanolamine Sulfite (1:1)

13. Triethanolamine Tartrate (1:1), (r-(r*,r*))-isomer

14. Triethanolamine Titanium Salt

15. Triethanolammonium Chloride

16. Trolamine

2.3.2 Depositor-Supplied Synonyms

1. Trolamine

2. 102-71-6

3. 2,2',2''-nitrilotriethanol

4. Sterolamide

5. Tris(2-hydroxyethyl)amine

6. Daltogen

7. Nitrilotriethanol

8. Triethylolamine

9. Trihydroxytriethylamine

10. Thiofaco T-35

11. Triethanolamin

12. Sting-kill

13. Ethanol, 2,2',2''-nitrilotris-

14. Tri(hydroxyethyl)amine

15. Tris(beta-hydroxyethyl)amine

16. Nitrilo-2,2',2''-triethanol

17. Sodium Isa

18. Alkanolamine 244

19. Teoa

20. Tea (amino Alcohol)

21. 2,2',2''-nitrilotris(ethanol)

22. Nitrilotris(ethanol)

23. 2-[bis(2-hydroxyethyl)amino]ethanol

24. Tris(hydroxyethyl)amine

25. Triethanolamin-ng

26. H3tea

27. Triaethanolamin-ng

28. Trolamine [inn]

29. 2,2',2-nitrilotriethanol

30. N(ch2ch2oh)3

31. Mobisyl

32. 2,2',2''-nitrilotrisethanol

33. Trola

34. Triethanolamine Homopolymer

35. 2,2',2''-trihydroxytriethylamine

36. Poly(triethanolamine) Ether

37. Trihydroxyethylamine

38. Trolamine (nf)

39. Trolamine [nf]

40. Mfcd00002855

41. Nsc 36718

42. Mobisy (tn)

43. Triethylamine, 2,2',2''-trihydroxy-

44. Triethanolamine Condensate Polymer

45. Ethanol, 2,2',2''-nitrilotri-

46. Ethanol, 2,2',2''-nitrilotris-, Homopolymer

47. Nsc-36718

48. Nciopen2_004601

49. 2,2',2"-nitrilotriethanol

50. 2-[bis(2-hydroxyethyl)amino]ethan-1-ol

51. 9o3k93s3tk

52. 2,2',2-nitrilotris(ethanol)

53. Chebi:28621

54. 2,2',2''-nitrilotris[ethanol]

55. Ncgc00159411-02

56. Dsstox_cid_1392

57. Tri-beta-hydroxy Ethylamine

58. Dsstox_rid_76134

59. Dsstox_gsid_21392

60. 64114-46-1

61. Caswell No. 886

62. Biafine

63. Tris(2-hydroxyethyl) Amine

64. Cas-102-71-6

65. Ccris 606

66. Hsdb 893

67. Triethanol Amine

68. Einecs 203-049-8

69. 2,2,2-nitrilotriethanol

70. Epa Pesticide Chemical Code 004208

71. Unii-9o3k93s3tk

72. Ethanolamines

73. 2,2',2'-nitrilotriethanol

74. Cerumenex

75. Alkano

76. Mobisy

77. Ai3-01140

78. Ethanol, 2,2',2'-nitrilotris-

79. Triethanolamine 85%

80. Triethanolamine 99%

81. Mobisyl (salt/mix)

82. Triethanolamine, Usp

83. Trolamine [ii]

84. Trolamine [hsdb]

85. Tris(b-hydroxyethyl)amine

86. Trolamine [vandf]

87. 2,2''-nitrilotriethanol

88. Bmse000379

89. Trolamine [mart.]

90. Ec 203-049-8

91. Nitrilo-2,2''-triethanol

92. Schembl1146

93. Trolamine [who-dd]

94. Triethanolamine [mi]

95. Oprea1_614203

96. Tris-(2-hydroxyethyl)-amine

97. Wln: Q2n2q2q

98. Tris(beta -hydroxyethyl)amine

99. 2,2''-nitrilotris[ethanol]

100. Bidd:er0261

101. Triethanolamine [iarc]

102. Triethanolamine [inci]

103. Ethanol,2',2''-nitrilotri-

104. Triethanolamine [vandf]

105. Tris(.beta.-hydroxyethyl)amine

106. Chembl446061

107. Ethanol,2',2''-nitrilotris-

108. Triethanolamine, Lr, >=99%

109. 2,2',2'-nitrilotris-ethanol

110. 2,2'2''-nitrilotris-ethanol

111. Trolamine [ep Impurity]

112. 2,2', 2''-nitrilotriethanol

113. 2,2',2quot -nitrilotriethanol

114. Dtxsid9021392

115. Trolamine [ep Monograph]

116. 2,2',2''-nitrilotri-ethanol

117. 2,2',2''-nitrilotris-ethanol

118. Nitrilo-2,2',2quot -triethanol

119. Triethanolamine, P.a., 99.0%

120. Triethanolamine, Ar, >=99.5%

121. Zinc896409

122. Triethanolamine 99% Reagent Grade

123. Triethylamine,2',2''-trihydroxy-

124. Adal1017515

125. Hy-b1809

126. Nsc36718

127. Tox21_113166

128. Tox21_202062

129. Tox21_300527

130. Triethanolamine, >=99.0% (gc)

131. 2,2',2''-trihydroxy-triethylamine

132. Stl264185

133. Triethanolamine, Reagent Grade, 98%

134. Akos000119997

135. Cs-5859

136. Db13747

137. 637-39-8 (unspecified Hydrochloride)

138. Smp2_000190

139. Tea, 0.2m Buffer Solution, Ph 7.0

140. Tea, 0.2m Buffer Solution, Ph 8.0

141. Ncgc00159411-03

142. Ncgc00159411-04

143. Ncgc00159411-05

144. Ncgc00159411-06

145. Ncgc00254460-01

146. Ncgc00259611-01

147. 7376-31-0 (unspecified Sulfate Salt)

148. Bp-21029

149. Ls-13235

150. Triethanolamine, Usp, 99.0-107.4%

151. 7376-31-0 (unspecified Sulphate Salt)

152. Triethanolamine, Bioultra, >=99.5% (gc)

153. Triethanolamine, Analytical Reference Material

154. Triethanolamine, Saj First Grade, >=98.0%

155. C06771

156. D00215

157. Triethanolamine, Jis Special Grade, >=98.0%

158. Triethanolamine, Puriss. P.a., >=99% (gc)

159. Triethanolamine, Vetec(tm) Reagent Grade, 97%

160. Q424314

161. Sr-01000944572

162. J-525067

163. Sr-01000944572-1

164. B886ef22-aca3-4597-9c73-a087e02f54a7

165. Trolamine, European Pharmacopoeia (ep) Reference Standard

166. Trolamine, United States Pharmacopeia (usp) Reference Standard

167. Triethanolamine, Puriss., Meets Analytical Specification Of Nf, >=99% (gc)

168. Trolamine, Pharmaceutical Secondary Standard; Certified Reference Material

169. Triethanolamine, Pharmagrade, Usp, Manufactured Under Appropriate Gmp Controls For Pharma Or Biopharmaceutical Production.

2.4 Create Date
2004-09-16
3 Chemical and Physical Properties
Molecular Weight 149.19 g/mol
Molecular Formula C6H15NO3
XLogP3-1
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count4
Rotatable Bond Count6
Exact Mass149.10519334 g/mol
Monoisotopic Mass149.10519334 g/mol
Topological Polar Surface Area63.9 Ų
Heavy Atom Count10
Formal Charge0
Complexity55.7
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Therapeutic Uses

/EXPL THER/ This multicentered phase III trial was designed to compare an emulsion containing trolamine against the usual supportive care within each participating institution for patients with head and neck cancer undergoing radiation therapy. Patients with biopsy-proven squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx were randomly assigned to one of the following treatments: prophylactic trolamine emulsion, interventional trolamine emulsion, or declared institutional preference. The primary outcome was the reduction in grade 2 or higher skin toxicity, as per National Cancer Institute Common Toxicity Criteria version 2.0. Secondary outcomes included patient-reported quality of life (QOL). From October 2000 to April 2002, 547 patients from 51 institutions were entered onto the trial. The average age was 59 years. Patients were predominately male (79%) and most continued to use tobacco products (52%). The rates of grade 2 or higher radiation dermatitis were 79%, 77%, and 79% in the prophylactic, interventional, and institutional preference arms of the study, respectively. No significant differences in QOL were found. The results of this trial demonstrate no advantage for the use of trolamine in reducing the incidence of grade 2 or higher radiation dermatitis or improving patient-reported QOL. The use of 15 different local standards of care highlights the need to continue research that will result in evidence-based recommendations to reduce the burden of radiation dermatitis.

PMID:1664851 Elliott EA et al; J Clin Oncol 24 (13): 2092-7 (2006)


Triethanolamine salicylate has also been used as a nonsteroidal anti-inflammatory. Triethanolamine USP is also used as a pharmaceutical adjuvant or alkalizing agent, and in combination with a fatty acid (e.g., oleic acid, stearic acid) as an emulsifier (the triethanolamine soap formed lowers the surface tension of the aqueous phase). /Triethanolamine salicylate/

Bingham, E.; Cohrssen, B.; Powell, C.H.; Patty's Toxicology Volumes 1-9 5th ed. John Wiley & Sons. New York, N.Y. (2001)., p. V4 785


4.2 Minimum/Potential Fatal Human Dose

2= Slightly toxic: Probable oral lethal dose (human) 5-15 g/kg, between 1 pint & 1 qt for 70 kg person (150 lb).

Gosselin, R.E., R.P. Smith, H.C. Hodge. Clinical Toxicology of Commercial Products. 5th ed. Baltimore: Williams and Wilkins, 1984., p. II-106


4.3 Drug Indication

Trolamine is used as an alkalizing agent, surfactant, and counter-ion in cosmetic and pharmaceutical formulations. It is not considered to be an active pharmacological ingredient and so has no official indication.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Acts as a surfactant or alkalizing agent to aid in emulsification and solubilizing of compounds or in raising the pH of a solution


5.2 ATC Code

D - Dermatologicals

D03 - Preparations for treatment of wounds and ulcers

D03A - Cicatrizants

D03AX - Other cicatrizants

D03AX12 - Trolamine


5.3 Absorption, Distribution and Excretion

Absorption

Dermal absorption of trolamine increases with the dose. This has been found to range from 19-28% in rats with doses of 68-276 mg/kg in 190 L of acetone without occlusion and from 60-80% in mice with doses of 79-1120 mg/kg in the same volume of acetone.


Route of Elimination

When orally administered to rats, the 53% of the trolamine dose was found to be excreted in the urine and 20% in the feces. 98% was excreted in the urine with intravenous administration.


The elimination of 14(C)triethanolamine from the blood of mice administered 1.0 mg/kg bw iv showed first-order biphasic kinetics with a rapid (0.58-hr half life) and a slow phase (10.2-hr half-life). The slow phase half-lives for elimination of triethanolamine in mice after dermal exposure to 1000 and 2000 mg/kg bw in acetone were 9.7 hr and 18.6 hr. Skin absorption rates (as blood concentration-time curves) after dermal application of aqueous and neat 14(C)triethanolamine to mouse skin (2000 mg/kg bw, enclosed by a glass ring) showed no significant change with the use of water as the vehicle.

IARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work). Available at: https://monographs.iarc.fr/ENG/Classification/index.php, p. V77 389 (2000)


In a dermal pharmacokinetic study, (14)C-triethanolamine was absorbed more slowly and less extensively in F344 rats than in C3H/HeJ mice. 48 hr after dermal application of (14)C-triethanolamine to mice (1,000 mg/kg dose), about 60% of the radioactivity was recovered from the urine and about 20% was recovered in the feces; less than 10% of the radioactivity was found in skin at the site of application. It was concluded that triethanolamine does not undergo extensive biotransformation in mice, since greater than 95% of the radioactivity recovered from the urine was identified as the parent compound.

Snyder, R. (ed.). Ethel Browning's Toxicity and Metabolism of Industrial Solvents. 2nd ed. Volume II: Nitrogen and Phosphorus Solvents. Amsterdam-New York-Oxford: Elsevier, 1990., p. 443


Triethanolamine was rapidly absorbed in orally dosed rats, and subsequently excreted mainly as unchanged parent compound in the urine. 24 hr after oral administration of triethanolamine (single dose of 2-3 mg/kg), 53% and 20% of the administered dose was recovered as the parent compound in the urine and feces, respectively.

Snyder, R. (ed.). Ethel Browning's Toxicity and Metabolism of Industrial Solvents. 2nd ed. Volume II: Nitrogen and Phosphorus Solvents. Amsterdam-New York-Oxford: Elsevier, 1990., p. 443


...After single oral administration to male rats, the excretion ratios of unchanged /triethanolamine/ in the urine and feces for one day were 53% and 20% of the dose, respectively.

Kohri N et al; Arch Pract Pharm 42: 342-348 (1982)


For more Absorption, Distribution and Excretion (Complete) data for TRIETHANOLAMINE (8 total), please visit the HSDB record page.


5.4 Metabolism/Metabolites

Trolamine is excreted mostly as the unchanged compound. No diethanolamine or ethanolamine has been found. Very small amounts of trolamine glucuronide have been detected but not quantified.


...N-nitrosodiethanolamine, known carcinogen and mutagen, ...may not be the main mutagenic product.

PMID:100210 Hoshino H, Tanooka H; Cancer Res 38 (11): 3918-21 (1978)


After multiple oral administration to male and female rats, triethanolamine was mainly excreted unchanged. The urinary and fecal excretion ratio of unchanged triethanolamine remained constant throughout the treatment period (for five to six days) in both males and females. A small amount of triethanolamine (1.4-2.7%) was excreted as glucuronide conjugates.

IARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work). Available at: https://monographs.iarc.fr/ENG/Classification/index.php, p. V77 390 (2000)


The biotransformation of 14(C)triethanolamine to monoethanolamine and diethanolamine was specifically investigated in mice after both intravenous and dermal treatments. Neither of the hypothetical metabolites was detected in urine (by mass spectral analysis), whereas more than 95% of the radioactivity detected in urine was identified as unchanged triethanolamine. In vitro, triethanolamine had an inhibitory effect on the incorporation of 32(P)phosphate into phospholipids from rabbit and human tissues. Cytochrome P450 monooxygenasedependent oxidative N-dealkylation of triethanolamine does occur in microorganisms, with formation of diethanolamine, ethanolamine and glyoxylate as reaction products.

IARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work). Available at: https://monographs.iarc.fr/ENG/Classification/index.php, p. V77 389 (2000)


To determine potential nitrosation of triethanolamine (TEA) to N-nitrosodiethanolamine (NDELA) at different physiological conditions of the GI tract, in vitro NDELA formation was examined in aqueous reaction mixtures at several pHs (2-10) adjusted with acetic, sulfuric or hydrochloric acids or in cultures of mouse cecal microflora incubated. In vivo NDELA formation was also determined in blood, ingesta, and urine of female B6C3F1 mice after repeated dermal, most relevant human route, or single oral exposure to 1000 mg/kg TEA in the presence of high oral dosages of NaNO(2). Appropriate diethanolamine (DEA) controls were included to account for this impurity in the TEA used. Samples were analyzed for NDELA using GC/MS. The highest degree of nitrosation of TEA to NDELA (approximately 3%) was observed in the in vitro cultures at pH 4 and acetic acid with lower amounts obtained using sulphuric acid ( pproximately 1.3%) and hydrochloric acid (approximately 1.2%). At pH 7, <1% of the TEA was nitrosated to NDELA and at pH 2 (HCl) or pH 10 (NaOH) no NDELA was found above the limit of detection. In incubated cultures containing cecal microflora and nutrient broth, only 0.68% of TEA was nitrosated to NDELA. No NDELA was formed in rats repeatedly dermally dosed with TEA at the limits of detection in blood (0.001 ug/mL, ppm), ingesta (0.006 ug/mL, ppm), and urine (0.47 ug/mL, ppm). Levels of NDELA measured in blood and ingesta after a single oral dose of TEA and NaNO(2) were less than those in DEA controls. These findings in toto confirm the lack of any significant formation of NDELA from TEA in vivo.

PMID:15905009 Saghir SA et al; Regul Toxicol Pharmacol 43 (1): 10-8 (2005)


For more Metabolism/Metabolites (Complete) data for TRIETHANOLAMINE (6 total), please visit the HSDB record page.


5.5 Biological Half-Life

The elimination of 14(C)triethanolamine from the blood of mice administered 1.0 mg/kg bw intravenously showed first-order biphasic kinetics with a rapid (0.58-hr half life) and a slow phase (10.2-hr half-life). The slow phase half-lives for elimination of triethanolamine in mice after dermal exposure to 1000 and 2000 mg/kg bw in acetone were 9.7 hr and 18.6 hr.

IARC. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Geneva: World Health Organization, International Agency for Research on Cancer, 1972-PRESENT. (Multivolume work). Available at: https://monographs.iarc.fr/ENG/Classification/index.php, p. V77 389 (2000)


The blood half-life of triethanolamine equivalents after iv injection (1 mg/kg) or dermal application (1000 mg/kg) of (14)C-triethanolamine in mice was about 9.5 hr.

Snyder, R. (ed.). Ethel Browning's Toxicity and Metabolism of Industrial Solvents. 2nd ed. Volume II: Nitrogen and Phosphorus Solvents. Amsterdam-New York-Oxford: Elsevier, 1990., p. 443


5.6 Mechanism of Action

As an amine, trolamine is capable of accepting a hydrogen to form hydroxide and a conjugate acid. This raises the pH of the solution. As a surfactant, it can lower the interfacial tension in a mixture or solution to prevent separation of emulsions or precipitation of a compound out of solution.